Amphista Therapeutics announces first patient dosed in AMX-883 Phase 1 clinical trial for acute myeloid leukemia

Amphista Therapeutics Limited ('Amphista'), a leader in the discovery and development of non-cereblon / VHL targeted protein degradation (TPD) medicines, today announced dosing of the first patient in a Phase…

Continue ReadingAmphista Therapeutics announces first patient dosed in AMX-883 Phase 1 clinical trial for acute myeloid leukemia

Researchers followed glucose monitor users for three years and found a possible kidney benefit

A study of more than 25,000 analytical group assignments involving high-risk adults with type 2 diabetes found that sustained real-time continuous glucose monitoring (rtCGM) was associated with substantial improvements in…

Continue ReadingResearchers followed glucose monitor users for three years and found a possible kidney benefit